Gut microbiome of women with a history of recurrent UTI depleted in microbial richness, butyrate-producing bacteria
Race as a variable in risk prediction model can be replaced by history of UTI and duration of fever without affecting accuracy
Researchers conducted a study to assess the effect of an antibiotic stewardship program on the use of appropriate antibiotic therapy among patients with urinary tract infections in the ED.
Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem with activity against uropathogenic Enterobacterales.
The phase 3 CERTAIN-1 study compared the efficacy and safety of cefepime-taniborbactam to meropenem in 661 adults with cUTI.
Incidence of antibiotic-treated UTI during 12-month treatment period noninferior for methenamine hippurate versus prophylactic antibiotics
MV140 is a sublingual vaccine of whole-cell inactivated bacteria that may be an alternative to frequent antibiotics for recurrent urinary tract infections.
In a study, IV fosfomycin appeared less effective than IV ceftriaxone or meropenem for bacteremic UTI caused by multidrug-resistant E. coli, but the drug may be considered for selected patients with these infections, according to investigators.
Researchers conducted a study to assess the safety and efficacy of aminoglycosides or polymyxin monotherapy for the treatment of adults with complicated urinary tract infections caused by extensively drug-resistant Pseudomonas aeruginosa.
The application includes data from the phase 3 ADAPT-PO trial, which evaluated the efficacy and safety of tebipenem HBr in 868 adults with cUTI or acute pyelonephritis.